Table 2.
Group | T0 baseline |
T1 16 weeks |
T2 28 weeks |
∆ (T1-T0) | ∆ (T2-T0) | |
---|---|---|---|---|---|---|
ADAS-cog | AG | 29.38 (9.43) | 25.30 (11.33) | 26.28 (10.73) a | 4.08 (7.73) | 3.10 (6.01) a |
DG | 30.15 (9.16) | 28.18 (9.78) | 31.25 (10.71) | 1.97 (2.08) | −1.10 (3.42) | |
CIBIC-Plus | AG | N | 3.07 (1.03) a | 4.08 (0.81) a | N | N |
DG | N | 3.69 (0.95) | 4.92 (0.77) | N | N | |
ADCS-ADL23 | AG | 49.44 (11.62) | 47.85 (11.22) | 48.18 (11.32) | 1.59 (6.11) | 1.26 (6.54) |
DG | 50.13 (13.57) | 48.20 (13.16) | 49.43 (13.45) | 1.92 (3.03) | 0.69 (3.05) | |
NPI | AG | 9.28 (2.49) | 7.25 (2.69) | 8.13 (2.78) | 2.02 (0.59) | 1.15 (0.60) |
DG | 8.97 (2.69) | 7.61 (2.30) | 9.31 (2.42) | 1.36 (0.57) | −0.33 (0.58) |
aindicates significance between the two study groups (p < 0.05)
N indicates not determined